Immune therapies, or check point inhibitors, have been very successful in a subset of patient with multiple different types of malignancies and has changed their trajectory tremendously, explained Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology, Northwestern University.
Immune therapies, or check point inhibitors, have been very successful in a subset of patient with multiple different types of malignancies and has changed their trajectory tremendously, explained Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology, Northwestern University.
Transcript
How have novel therapies changed the cancer treatment landscape?
The premise of precision medicine, first and foremost, is to match the right patient with the right treatment at the right time. Immune therapies, or check point inhibitors, have been very successful in a subset of patient with multiple different types of malignancies and has changed their trajectory tremendously.
For example, melanoma has had a very high success rate with the immunologic therapies. As we all know, it’s where we started out in. President Jimmy Carter had actually gotten an experimental checkpoint inhibitor for his melanoma, which had traveled to his brain. He has been disease free for a number of years, potentially even cured, which doesn’t happen often, but it can happen with these therapies.
Additionally, there are lung cancer patients who have also benefitted tremendously form these therapies. Case and point are patient who have had greater than 50% tumor proportion score of PD-L1. These particular patients tend to have a very strong and lasting response to these drugs. However, it’s only about half of these patients who have these parameters.
I think there’s a lot of questions that still remain unanswered with them. I think they’re great therapies, they’re here to stay, and they do benefit some of our patients. But, my questions still remain: what is the proper sequencing of many of these agents? What should we be doubling them up with? Should we be doubling them up with anything? And, why are there patients who, in all rightfulness, should be responding to them and are not? Is it because of their innate immune systems? Is it because of other underlying comorbidities? Is it due to other problems within the microenvironment of these tumors? Even their microbiome, that remains pretty unclear at this time, and I think there’s a lot of work to be done.
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
CMS Leaders Describe Their Partnership to Align Programs, Address ACOs’ Concerns
April 11th 2024As CMS’ suite of value-based and accountable care models evolves, leaders from across the agency detailed how they are working together to streamline quality reporting and encourage the move to a population health mindset while addressing providers’ concerns.
Read More